About Alcresta Therapeutics

Daniel Orlando is the Chief Executive Officer of Alcresta Therapeutics.  He joins the team with more than 18 years of executive management and corporate development experience leading organizations through rapid growth in the development, manufacturing and commercialization of therapeutics and biologics.  Prior to joining Alcresta Therapeutics, Daniel was most recently the Chief Operating Officer of Vericel Corporation, an autologous cell therapy company, which purchased the cell therapy and regenerative medicine business unit from Sanofi Genzyme.  During his tenure, he led every function at Vericel, most recently, Sales, Marketing, Manufacturing, Engineering, and Research & Development.   Before joining Vericel, Daniel was one of Takeda North America’s early employee’s and held executive positions in Business Development, Marketing, and Sales as well as similar developmental roles at Abbott Laboratories.  Daniel holds a BA in Economics with Honors from the University of Florida and an MBA from Florida Atlantic University.

Bill Scheinler is Chief Legal and Compliance Officer and Secretary at Alcresta Therapeutics. He brings years of experience as a leader in public and private medical device and pharmaceutical companies, and as a specialist in compliance, contracting, mergers and acquisitions, and licensing. Bill was previously Vice President, Associate General Counsel for Ikaria, Inc., where he helped transform a business that was expected to face generic competition into a durable customer service-focused franchise with growing revenues, resulting in a five-fold increase in enterprise value. Among his responsibility at Ikaria were driving and supporting multiple in-licensing and product acquisition/divestiture transactions, the spin-out of the company’s R&D business to a stand-alone public company, developing effective and compliant business sustainability strategies, resolving complex, high value commercial disputes, and overseeing company contracting, including contracts with customers and key suppliers. Prior to joining Ikaria, Bill was Associate General Counsel at VIASYS Healthcare, Inc., a public healthcare technology company with four business units focused in respiratory care, neurology, medical disposables, surgical products, and orthopedics. At VIASYS, he supported the company’s global expansion strategy, including the acquisition of 11 companies to grow the company’s revenues by four times and enterprise value by more than three times. Before joining VIASYS, Bill was in the business and finance group at Morgan, Lewis & Bockius LLP, with a focus in technology transactions, licensing, outsourcing, supply and distribution arrangements, and mergers and acquisitions. Bill holds a J.D. from Temple University - James E. Beasley School of Law and an M.A. in International Policy Analysis from Middlebury Institute of International Studies at Monterey.

Jason Weiner is the Chief Strategy and Business Development Officer of Alcresta Therapeutics. He joins the team with more than 17 years of industry and strategy consulting experience in the biopharmaceutical industry.  Prior to Alcresta, Jason was the Vice President of Marketing and Market Access at Vericel Corporation, an autologous cell therapy company, where during his tenure he led all marketing and market access related activities for the cell therapy and regenerative medicine franchise. Included was the expansion and build-out of the commercial team and development of an innovative patient access and distribution program. Jason held developmental Sales roles at Pfizer and Astellas before leading strategy engagements as a consultant at Charles River Associates where he advised on issues related to customer engagement, payer marketing, drug launches, physician research, sales force alignment, market access, and pricing strategy. Jason holds a BA in History from Union College and an MBA from Boston College.

Chris Arnold is the Chief Commercial Officer at Alcresta Therapeutics. With over 25 years of experience in the medical device industry—including more than 17 years in commercial leadership and over a decade in executive leadership—Chris brings a wealth of expertise in driving business growth and market expansion.

Before joining Alcresta, Chris served as Vice President of Sales at both Cogentix Medical (acquired by Laborie) and Linden-owned Z-Medica (acquired by Teleflex), two high-growth, early-stage commercial companies. In these roles, he led strategic sales initiatives, fostered a culture of innovation and collaboration, launched multiple new products, and successfully scaled both organizations for rapid growth.

Chris began his medical device career at Boston Scientific, where he held progressively senior roles, including Sales Director of the high-growth Women’s Health Division and Executive Director of Sales for the Urology Division. He holds a B.S. in Business Administration from Centenary College.

Chris Parrish is the Chief Operations Officer of Alcresta Therapeutics. He joins Alcresta with more than 25 years of biotech and medical device industry experience. Prior to joining Alcresta, Chris was Vice President of Manufacturing at Vericel Corporation, an autologous cell therapy company, where during his tenure he also led quality and worked in research and development. In addition to leading Manufacturing Operations through completion of clinical trials, Chris has also supported product launch and commercial success of cell therapy products. Chris started his career with Pfizer as a scientist in research and development and quality.

Michael Yeh, MD, MPH, MBA is the Chief Medical Officer at Alcresta Therapeutics. He joined the company in March 2025 and leads Medical Affairs, Clinical Development & Operations, and Research & Development.

Dr. Yeh brings over 20 years of biopharmaceutical industry experience, primarily in medical affairs. Prior to joining Alcresta, he served as Head of Medical Strategy and Evidence Generation for systemic pegcetacoplan at Apellis Pharmaceuticals, where he led the global launch of pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) and directed global publications, alliance management, and post-approval evidence generation.

Earlier in his career, he held medical affairs leadership roles at Millendo Therapeutics, GE Healthcare, Sobi, Biogen, Novartis, and Genzyme, supporting both U.S. and global programs. His work has focused on ultra-orphan diseases and real-world evidence strategies. He also spent four years at the Boston Consulting Group, advising healthcare and biopharma clients on strategic initiatives.

Dr. Yeh began his career as an internal medicine physician after completing his residency at the University of California, San Francisco, practicing and teaching for six years before transitioning to industry.

He holds an M.D. from the University of California, San Francisco, an M.P.H. from the University of California, Berkeley, and an M.B.A. from the University of Michigan. He earned his B.S. from Yale University.

Ian Vawter is a medical device finance professional with experience in a variety of enterprises, from pre-commercial start-ups to multi-national conglomerates. Joining Alcresta in 2025 he brings over 25 years of experience in the medical device industry with a broad range of device experiences, ranging from capital equipment to biological implants. He has held ever-increasing finance roles with companies such as Channel Medsystems, Tepha, CSA Medical, iWalk, Tissue Science Laboratories, Covidien and EDAP TMS.

Greta Loring, Ph.D is the Vice President of Research and New Product Development at Alcresta Therapeutics. With over two decades of experience spanning academic research, pharmaceutical innovation, and medical device development, Greta leads the development of enzyme-based therapeutics designed to improve the lives of patients with rare gastrointestinal disorders at Alcresta.

Before joining Alcresta, Greta held leadership roles at Enzymatics (acquired by Qiagen), Alnara Pharmaceuticals (acquired by Eli Lilly), and Altus Pharmaceuticals, where she drove innovation in enzyme replacement therapies and molecular biology reagents. Her work has contributed to multiple FDA filings and clinical studies, and she is a co-author on numerous peer-reviewed publications in journals such as Annals of Surgery, Clinical Nutrition, and Journal of Molecular Biology.

Greta earned her Ph.D. in Biochemistry from the University of Iowa, where she was honored with the Subramanian Best Doctoral Dissertation Award and multiple prestigious fellowships. Her postdoctoral work at Dartmouth Medical School focused on mechanistic studies of ubiquitin pathway enzymes and cancer biology, laying the foundation for her translational approach to science.

Jim Kevil is the VP of Finance, bringing over 18 years of corporate finance and leadership experience in the medical device, business analytics, and biotech industries. Prior to joining Alcresta, Jim held various finance positions at Patrys Ltd and Eurofins while living in Australia. He holds a B.S. in Finance from University of South Carolina and an M.B.A. from Rutgers University.

Jennifer Blakely is the Senior Director of Human Resources of Alcresta, bringing over 25 years of experience in the Human Resources field.

Prior to joining Alcresta Therapeutics, Jennifer was most recently the Human Resources Business Partner, Site Lead for AstraZeneca’s Massachusetts office. Before her time at AstraZeneca, she held multiple senior HR leadership roles within the technology sector, where she gained extensive experience in strategically growing and scaling HR functions to support organizational goals.

Jennifer holds a Bachelor’s degree in Psychology from Framingham State University, a Master’s degree in Industrial/Organizational Psychology from Bridgewater State University, and a Certification in Human Resources Management from Bentley University.